ALISO VIEJO, Calif., Feb. 09, 2017 -- NVISION Eye Centers—a national leader in providing the finest suite of ophthalmology services for patients including: custom and Topographic LASIK, KAMRA Inlay, cataract surgery and other vision correction procedures—is pleased to announce today the promotion of Brooke Jakovich to Vice President of Operations.
"Brooke has been an exemplary team player at NVISION Eye Centers, embracing every challenge put before her and excelling in many key roles within the organization,” says NVISION Eye Centers' president James Pereyra. "Since first joining the company as an Area Manager supporting our Fullerton location, she has demonstrated a strong aptitude for partnering with referring doctors, patients and teammates. Her breadth and depth of experience within the company, is proof of her commendable abilities not only as a team player, but also a true leader."
Over the course of ten years, Jakovich has held many positions with NVISION from managing the organization’s largest practice and flagship location in Newport Beach, California, to launching NVISION’s cataract service line in 2012. Most recently, she joined the leadership team as the head of operations where she was responsible for creating better communication channels between the clinics and support center, establishing mentorship and training programs, and developing the tools to support the Executive Directors in their respective clinics.
“This is an exciting time to be at NVISION, and I am honored to be taking the reins in this leadership capacity,” says Brooke Jakovich. “Beginning my professional career trajectory at NVISION afforded me a unique and insightful understanding of the inner workings of the company, from a tactical perspective. I look forward to helping my team cultivate new business opportunities and continue to grow within this thriving industry.”
Jakovich received her BA from California Sate University, Fullerton, graduating summa cum laude.
For more information, call (877) 455-9942 or visit: http://www.nvisioncenters.com.
ABOUT NVISION EYE CENTERS: NVISION Eye Centers is the premier provider of LASIK and cataract surgery in the U.S., with centers in California, Nevada, Oregon, Arizona and Toronto, Canada. An innovative leader in ophthalmology, NVISION is dedicated to providing the best patient experience through the use of the latest technology and treatment by the most talented and experienced surgeons in the industry. NVISION was founded in 2010 by Tom Tooma, M.D., one of the earliest pioneers of LASIK who has performed more than 100,000 procedures throughout his esteemed career. With more than 1,900 eye doctors referring their patients and trusting their own eyes to NVISION surgeons, NVISION Eye Centers is the Eye Doctors' #1 Choice®. For more information, visit www.NVISIONCenters.com or call (877) 455-9942.


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



